
Trace Neuroscience Launches Global Clinical Program for ALS Therapy TRCN-1023
Trace Neuroscience Launches Global Clinical Development Program for TRCN-1023 in ALS Trace Neuroscience, Inc., a biopharmaceutical company focused on advancing genomic medicine for people living with neurodegenerative diseases, has announced…












